NCT06015997View on ClinicalTrials.gov

Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

November 1, 2025

Conditions
ATTR Amyloidosis Wild TypeSevere Aortic StenosisAortic Valve StenosisMiddle East Studies
All Listed Sponsors
lead

Jordan Collaborating Cardiology Group

OTHER

NCT06015997 - Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR | Biotech Hunter | Biotech Hunter